The observed capacity of the Aβ42-neutralizing antibody aducanumab to mitigate PTH hypersecretion in vivo in the murine models and ex vivo in human parathyroid tissue presents an intriguing possibility for repurposing an FDA-approved agent for medical management of hyperparathyroidism. The gene discussed is PTH; the disease is hyperparathyroidism.